© Borgis - Postepy Fitoterapii 4, s. 195-205
Tadeusz Bodalski, *Katarzyna Karłowicz-Bodalska1, 2
Ginkgo biloba L. – miłorz±b dwuklapowy (chemizm i działanie biologiczne)
Ginkgo biloba L. – chemistry and activity
1Hasco-Lek S.A. we Wrocławiu
2Zakład Farmacji Przemysłowej Wydziału Farmaceutycznego AM we Wrocławiu
Summary
The leaves of Ginkgo biloba have become in Europe and USA a widely used herbal remedies for the symptomatic treatment of central nervous system diseases and of peripheral and cerebral circulatory disorders. The literature review of selected papers (2000-2006) connected with a problem of pharmacological activity and clinical use of standardized extract from Ginkgo biloba L. (EGb 761) has been presented below. The extract EGb 761 contains the determined amounts of flavonoids, mainly flavonol O-glycosides with a glycoside binding in position 3 and 7 phenol aglycone (quercetine, kaempferol, isorhamnetine) and the proanthocyanidins. The another group of active substances in the extract EGb 761 are the lactones (diterpenes – ginkgolides and sesquiterpen – bilobalid) with a unique structure, earlier unknown in the plant world. The both groups of active substances act as antioxidants, free radical scavengers, enzyme inhibitors and cation chelators. The current studies inform that the many sided therapeutic activity of extract EGb 761 is a result of above antioxidative and free radicals scavenging properties of both groups of substances. These properties are of great importance for the obtaining of positive results in the treatment of many diseases with EGb extract. The EGb extract is mainly useful in the therapy of mild to moderate various origin dementia, senile neurosensorial diseases (vertigo, tinnitus) also by insufficiency of cerebral circulation. The studies show that the main indication of extract from the leaves Ginkgo biloba is the therapy of cognitive dysfunction – cerebral insufficiency, intermittent claudication (improving of walking), therapy of vertigo and tinnitus of circulatory origin.
Key words: ginkgo biloba l., chemical composition, biological properties, health activity
Pi¶miennictwo
1. Smith J.V., Luo Y.: Studies on molecular mechanisms of Ginkgo biloba extract. Appl. Microbiol. Biotech. 2004, 64, 465. 2. Zimmermann M., Colciaghi F. i wsp.: Ginkgo biloba extract: from molecular mechanisms to the treatment of Alzheimer´s disease. Cell. Mol. Biol. 2002, 48, 613. 3. DeFeudis F.V., Drieu K.: Ginkgo biloba extract (Egb 761) and CNS functions: basic studies and clinical applications. Curr. Drug. Targets 2000, 1, 25. 4. Ponto L.L.B., Schultz S.K.: Ginkgo biloba extract: Review of CNS effects. Ann. Clin. Psych. 2003, 15, 109. 5. Kleijnen J., Knipschild P.: Ginkgo biloba; The Lancet –Drug Profiles 1992, 340, 1136. 6. Spiess E., Juretzek W.: Ginkgo Hagers Handbuch der pharm. Praxis 2003 B. 7. Ai-Hua-Xu, Hua- Sheng Chen i wsp.: World J. Gastroenterol. 2003, 9, 2424. 8. Vatanabe C.M., Wolffram S. i wsp.: The in vivo neuromodulatory effects of the herbal medicine Ginkgo biloba. Proc. Natl. Acad. Sci. USA 2001, 98, 6577. 9. Sticher O., Meier B., Hasler A.: Ginkgo biloba in TA van Beck (ed.) Medicinal and aromatic plants – Industrial Profiles. Harwood, Amsterdam 2000, 12, 179. 10. Beck T.A.: Chemical analysis of Ginkgo biloba leaves and extracts (review). J. Chromatogr. A 2002, 967, 21. 11. Beck T.A., Bombardelli E. i wsp.: Ginkgo biloba L. Fitoter. 1998, 69, 195. 12. Hasler A.: Ginkgo biloba w TA van Beck (Ed.) Medicinal and Aromatic Plants – Industrial Profiles Harwood, Amsterdam 2000, 12, 109. 13. Ellnein-Wojtaszek M.: Phenolic acids from Ginkgo biloba L. Part I. Qualitative analysis of free and liberated by hydrolysis phenolic acids. Acta Pol. Pharm. Drug Res. 1997, 54, 225. 14. Ellnein-Wojtaszek M.: Phenolic acids from Ginkgo biloba L. Part II. Quantitative analysis of free and liberated by hydrolysis phenolic acids. Acta Pol. Pharm. Drug Res. 1997, 54, 229. 15. Ellnein-Wojtaszek M., Mirska I.: Phenolic acids from Ginkgo biloba L. Part III. Antimicrobial activity of phenolic acids. Acta Pol. Pharm. Drug Res. 1998, 55, 81. 16. European Pharmacopeia Comission. Pharmeuropa 1999, 11, 333, 337. 17. Blumenthal M., Busse W.R., Goldberg A. i wsp.: The complete German Comission E Monographs: Therapeutic Guide to Herbal Medicines. Austin: Am. Botanical Council 1998, 136. 18. MacLennan K.M., Darlington C.L., Smith P.F.: The CNS effect of Ginkgo biloba extracts and ginkgolide B. Progr. Neurobiol. 2002, 67, 235. 19. Diamond B.J., Shiflett S.C. i wsp.: Ginkgo biloba extract: mechanisms and clinical indications. Arch. Phys. Med. Rehabil. 2000, 81, 668. 20. DeFeudis F.V.: A brief history of Egb 761 and its therapeutic uses. Pharmacopsychiatry 2003, 36, 2. 21. Ernst E., Pittler M.H.: Ginkgo biloba for dementia: a systematic review of double-blind, placebo-controlled trials. Clin. Drug Invest. 1999, 17, 301. 22. Gertz H.J., Kiefer M.: Review about Ginkgo biloba special extract Egb 761 ( Ginkgo). Curr. Pharmacol. Des. 2004, 10, 261. 23. Winther K., Randlov C. i wsp.: Effects of Ginkgo biloba extract on cognitive function and blood pressure in elderly subjects. Curr. Ther. Res. 1998, 59, 881. 24. Dongen M., van Rossum E. i wsp: The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am. Geriatr. Soc. 2000, 48, 1183. 25. Liebgott T., Miollan M. i wsp.: Complementary cardioprotective effects of flavonoid metabolites and terpenoid constituents of Ginkgo biloba extract (EGb 761) during ischemia and reperfusion. Basic Res. Cardiol. 2000, 95, 368. 26. DeFeudis F.V.: Bilobalide and neuroprotection. Pharmacol. Res. 2002, 46, 565. 27. Weichel O., Hilgert M. i wsp.: Bilobalide, a constituent of Ginkgo biloba, inhibits NMDA-induced phospholipase A2 activation and phospholipid breakdown in rat hippocampus. Naunyn-Schmiedeberg´s Arch. Pharmacol. 1999, 360, 609. 28. Bastianetto S., Quirion R.: Egb 761 is a neuroprotective agent against β-amyloid toxicity. Cell. Mol. Biol. 2002, 48, 693. 29. Ellnein-Wojtaszek M., Kruczyński Z., Kasprzak J.: Analysis of the content of flavonoids, phenolic acids as well as free radicals from Ginkgo biloba L. leaves during the vegetative cycle. Acta. Pol. Pharm. Drug Res. 2001, 58, 205. 30. Ellnein-Wojtaszek M.: Miłorz±b dwuklapowy a wolne rodniki. Farmacja Polska 2002, 58, 63. 31. Ellnein-Wojtaszek M., Kruczyński Z., Kasprzak J.: Variations in the free radical scavenging activity of Ginkgo biloba L. leaves in the period of complete development of green leaves to fall of yellow ones. Food Chem. 2002, 79, 79. 32. Ellnein-Wojtaszek M., Kruczyński Z., Kasprzak J.: Investigation of the free radical scavenging activity of Ginkgo biloba L. leaves. Fitoter. 2003, 74, 1. 33. Gohil K: Genomic responses to herbal extracts: lessons from in vitro and in vivo studies with an extract of Ginkgo biloba. Biochem. Pharmacol. 2002, 64, 913. 34. Logani S., Chen Meng Cheng, Tran T. i wsp.: Actions of Ginkgo biloba related to potential utility for the treatment of conditions involving cerebral hypoxia. Life Sci. 2000, 67, 1389. 35. Gaudineau C., Beckerman R. i wsp.: Inhibition of human P 450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem. Biophys. Res. Comm. 2004, 318, 1072. 36. Luo Y., Smith J.V. i wsp.: Inhibition of amyloid beta-aggregation and caspase-3 activation by the Ginkgo biloba extract Egb 761. Proc. Natl. Acad. Sci. USA 2002, 99, 12197. 37. Jones F.A., Chatterjee S.S., Davies J.A.: Effects of bilobalide on amino acid release and electrophysiology of cortical slices. Amino Acids 2002, 22, 369. 38. Woo Connie W.H., Cheung F., Chan Vincent W.H. i wsp.: Homocysteine stimulates inducible nitric oxyde synthase expression in macrophages: Antagonizing effect of ginkgolides and bilobalide. Mol. Cell. Biochem. 2003, 243, 37. 39. Porsolt R.D., Roux S., Drieu K.: Evaluation of a Ginkgo biloba extract (EGb 761) in functional tests for monoamine oxidase inhibition. Arzneim.-Forsch. Drug Res. 2000, 50, 232. 40. Christen Y.: From clinical observations to molecular biology: Ginkgo biloba extract EGb 761 a success for reverse pharmacology. Curr. Top Neutraceut. Res. 2003, 1, 59. 41. Fowler J.S., Wang G.J. i wsp.: Evidence, that Ginkgo biloba extract does not inhibit MAO A and MAO B in living human brain. Life Sci. 2000, 66, 141. 42. Dongen van M., van Rossum E. i wsp: Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J. Clin. Epidemiol. 2003, 56, 367. 43. DeKosky S.T., Fitzpatrick A., Ives D.G. i wsp.: The Ginkgo evaluation of memory study: Design and baseline data of a randomized trial of Ginkgo biloba extract in prevention of dementia. Contemporary Clin. Trials 2006, 27, 238. 44. Tang Y., Lou F., Wang Y., Zhuang L.S.: Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba. Phytochem. 2002, 58, 1251. 45. Persson J., Bringlöv E., Nilsson L.G., Nyberg L.: The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers. Psychopharm. 2004, 172, 430. 46. Cieza A., Maier P., Pöppel E.: Effects on Ginkgo biloba on mental functioning in healthy volunteers. Arch. Med. Res. 2003, 34, 373. 47. Christen Y.: Oxidative stress and Alzheimer´s disease. Am. J. Clin. Nutr. 2000, 71, 621S. 48. Oken B.S., Storzbach D.M., Kaye J.A.: The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch. Neurol. 1998, 55, 1409. 49. McKenna D.J., Jones K., Hughes K.: Efficacy, safety and use of Ginkgo biloba in clinical and preclinical applications. Altern. Ther. Health Med. 2001, 7, 70. 50. Le Bars P.L.: Efficacy and safety of a Ginkgo biloba extract. Pub. Health Nutr. 2003, 3, 495. 51. Chavez M.L., Chavez P.I.: Ginkgo (Part 2): Clinical efficacy, dosage and adverse effects. Hosp. Pharm. 1998, 33, 1076. 52. Kennedy D.O., Scholey A.B., Wesnes K.A.: The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacol. 2000, 151, 416. 53. Stephen G.: Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. Am. J. Prev. Med. 1999, 16, 105. 54. Mahady G.B.: Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature. J. Cardiovasc. Nurs 2002 16, 21. 55. Rioufol G., Pietri S. i wsp.: Ginkgo biloba extract Egb 761 attenuates myocardial stunning in the pig heart. Basic Res. Cardiol. 2003, 98, 59. 56. Yamamoto S., Nakano B., Ishikawa C. i wsp.: Enhanced inhibitory effects of extracts from Ginkgo biloba L. leaves encapsulated in hybrid liposomes on the growth of tumor cells in vitro. Biochem. Engin. J. 2002, 12, 125. 57. Smith J., Luo Y.: Elevation of oxidative free radicals in Alzheimer´s disease models can be attenuated by Ginkgo biloba extract EGb 761. J. Alzheimer´s Dis. 2003, 5, 287.
otrzymano/received: 2006-11-06
zaakceptowano/accepted: 2006-12-04
Adres/address:
*Katarzyna Karłowicz-Bodalska
Hasco-Lek S.A.
ul. Żmigrodzka 242e, 51-131 Wrocław
tel. (0-71) 353-95-22
e-mail: hasco@hasco-lek.com.pl
